Clinical trials: Allogeneic Stem-Cell Transplant
Acute Myeloid Leukemia, Myelodysplastic Syndromes
IFN-α in Relapse Prevention.
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry…
- Trial name
- NCT07449286
- Testing
- IFN-α
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to…
- Conditions
- Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury
- Trial name
- NCT07613099
- Testing
- [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
MSC
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective approach for treating both benign and malignant blood disorders.
- Trial name
- NCT06171906
- Testing
- mesenchymal stromal cells
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- ShiCang Yu
Duchenne's Muscular Dystrophy
Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)
This research study is designed to evaluate the effects of human umbilical cord mesenchymal stem cells (UC-MSCs), on Duchenne's muscular dystrophy (DMD).
- Trial name
- NCT02235844
- Testing
- Umbilical Cord Mesenchymal Stem Cells
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Allergy and Asthma Consultants, Wichita, Kansas
Epstein-Barr Viraemia, Hematologic Diseases
Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation
Scientific context Epstein-Barr virus has a causal role in the pathogenesis of multiple distinct lymphomas. Post-transplant lymphoproliferative diseases (PTLD) are the most frequent EBV-induced proliferations.
- Conditions
- Epstein-Barr Viraemia, Hematologic Diseases, Allogeneic Disease
- Trial name
- EBVALLO (NCT03343834)
- Testing
- biological collection
- Where
- France
- Volunteers
- 138 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoid Leukemia, Acute, Myeloid Malignancy
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
This pilot study is being conducted to treat patients who have a certain type of malignancy (lymphoid or myeloid) with immune effector cells after a T-cell depleted allogeneic hematopoietic cell transplantation (TCD HSCT).
- Conditions
- Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
- Trial name
- NCT05350163
- Testing
- T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Guenther Koehne
Cytomegalovirus Infections, Haematological Malignancy
Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient
This study consists of two parts: 1) Part 1, a retrospective part on 250 consecutive patients following allogeneic haematopoietic stem cell transplant (allo-HSCT) at the Royal Melbourne Hospital from 2012 to 2017, inclusive, and…
- Conditions
- Cytomegalovirus Infections, Haematological Malignancy, Organ or Tissue Transplant; Complications, Immune Suppression
- Trial name
- CReSCT (NCT03806764)
- Testing
- Blood sampling
- Where
- Australia
- Volunteers
- 370 people
- Sponsor
- Melbourne Health
Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy is a rapidly developing novel approach in adoptive immunotherapy for tumors in recent years.
- Conditions
- Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Chimeric Antigen Receptor T-cell
- Trial name
- NCT07034755
- Testing
- autologous hematopoietic stem cell transplantation (ASCT) followed by CAR-T therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Breast Cancer, Iron Overload
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
RATIONALE: Deferasirox may be effective in treating iron overload caused by blood transfusions in patients who have undergone donor stem cell transplant.
- Conditions
- Breast Cancer, Iron Overload, Leukemia, Lymphoma
- Trial name
- NCT00602446
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myeloproliferative Disorders, Blood Cancer
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly patients with advanced stage MDS and MPD.
- Conditions
- Myeloproliferative Disorders, Blood Cancer, Myelodysplastic Syndromes
- Trial name
- NCT00185796
- Testing
- Total Lymphoid Irradiation (TLI), Anti-Thymocyte Globulin as Conditioning (ATG)
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Stanford University
Hematological Malignancies
Reduced Intensity Haploidentical Transplant for Hematological Malignancies
Many patients with hematological malignancies (leukemia, lymphoma, multiple myeloma) cannot undergo hematopoietic stem cell transplantation (HSCT) because they do not have a well matched donor.
- Trial name
- NCT01162096
- Testing
- Haploidentical Allogeneic Transplantation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
This pilot study is designed to evaluate outcomes with the combination of CPX-351 salvage therapy and haplo-cord graft stem cell transplantation for subjects with relapsed or refractory AML or myelodysplastic syndrome.
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Relapsed Adult Acute Myeloid, Myelodysplastic Syndromes, Previously Treated
- Trial name
- NCT03393611
- Testing
- CPX-351, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Weill Medical College of Cornell University
Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease
Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
This study is a prospective, multicenter, open-label, phase II clinical trial designed to evaluate the safety and efficacy of moxibustion in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) following…
- Conditions
- Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Graft-Versus-Host Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT07572669
- Testing
- Moxibustion, Moxibustion Twice Daily Plus Best Available Treatment (BID Group), Best Available Treatment (BAT)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Recurrent Plasma Cell Myeloma
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
This phase II trial studies how well a reduced intensity conditioning regimen after donor stem cell transplant works in treating patients with multiple myeloma that has come back (relapsed).
- Trial name
- NCT04205240
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Daratumumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Srinivas Devarakonda
Anemia, Aplastic, Amegakaryocytic Thrombocytopenia
Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias
Due to an overall and disease free survival of 85% to 100%, allogeneic blood or bone marrow stem cell transplantation using an HLA matched sibling donor is the therapy of choice for patients with severe aplastic anemia (SAA).
- Conditions
- Anemia, Aplastic, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Kostmann Syndrome
- Trial name
- NCT00244010
- Testing
- Allogeneic stem cell transplant
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Hematologic Malignancies, Graft-Versus-Host Disease
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
This Phase 1 clinical study is designed to examine the safety and feasibility of using anti-CD3/CD28 activated marrow infiltrating lymphocytes (MILs) as treatment of relapse after allogeneic hematopoietic cell transplantation…
- Trial name
- NCT02342613
- Testing
- Activated PTCy-MILs
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cytomegalovirus Infections
Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT
Human cytomegalovirus (CMV) is a benign infectious agent in the normal host, but in immunocompromised individuals, such as recipients of stem cell transplants, this virus is a major cause of morbidity and mortality.
- Trial name
- NCT01274377
- Testing
- CMV Specific T Cell donor lymphocyte infusion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Nelson Chao
Primary Myelofibrosis, Myeloproliferative Disorders
PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
A number of groups have demonstrated very low incidence of acute and chronic graft-versus-host disease (GVHD) with post-transplantation cyclophosphamide (PTCy) in haploidentical and unrelated allogeneic stem cell transplantation…
- Trial name
- NCT02806375
- Testing
- Allogeneic hematopoietic stem cell transplantation, Busulfan, Fludarabine monophosphate
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy or…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00053157
- Testing
- sargramostim
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Myelofibrosis, Acute Myelogenous Leukemia
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
This is a study of allogeneic stem cell transplantation with TBX-2400 in adult subjects with Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF).
- Trial name
- NCT04709458
- Testing
- TBX-2400
- Where
- 2 sites in Croatia, Italy
- Volunteers
- 10 people
- Sponsor
- Taiga Biotechnologies, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.